Literature DB >> 18854559

Evidence mounts for the efficacy of radioimmunotherapy for B-cell lymphomas.

Oliver W Press.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18854559      PMCID： PMC2652089          DOI： 10.1200/JCO.2008.18.5447

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  27 in total

1.  Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma.

Authors:  T E Witzig; C A White; G A Wiseman; L I Gordon; C Emmanouilides; A Raubitschek; N Janakiraman; J Gutheil; R J Schilder; S Spies; D H Silverman; E Parker; A J Grillo-López
Journal:  J Clin Oncol       Date:  1999-12       Impact factor: 44.544

Review 2.  Principles of radioimmunotherapy for hematologists and oncologists.

Authors:  O W Press; J Rasey
Journal:  Semin Oncol       Date:  2000-12       Impact factor: 4.929

3.  Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

Authors:  Thomas E Witzig; Leo I Gordon; Fernando Cabanillas; Myron S Czuczman; Christos Emmanouilides; Robin Joyce; Brad L Pohlman; Nancy L Bartlett; Gregory A Wiseman; Norman Padre; Antonio J Grillo-López; Pratik Multani; Christine A White
Journal:  J Clin Oncol       Date:  2002-05-15       Impact factor: 44.544

4.  High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation.

Authors:  Liliana Devizzi; Anna Guidetti; Corrado Tarella; Michele Magni; Paola Matteucci; Ettore Seregni; Carlo Chiesa; Emilio Bombardieri; Massimo Di Nicola; Carmelo Carlo-Stella; Alessandro M Gianni
Journal:  J Clin Oncol       Date:  2008-10-14       Impact factor: 44.544

5.  Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.

Authors:  Thomas E Witzig; Ian W Flinn; Leo I Gordon; Christos Emmanouilides; Myron S Czuczman; Mansoor N Saleh; Larry Cripe; Gregory Wiseman; Teresa Olejnik; Pratik S Multani; Christine A White
Journal:  J Clin Oncol       Date:  2002-08-01       Impact factor: 44.544

6.  Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas.

Authors:  John M Pagel; Nathan Hedin; Krishnan Subbiah; Damon Meyer; Robert Mallet; Donald Axworthy; Louis J Theodore; D Scott Wilbur; Dana C Matthews; Oliver W Press
Journal:  Blood       Date:  2002-11-21       Impact factor: 22.113

7.  High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis.

Authors:  Ajay K Gopal; Theodore A Gooley; David G Maloney; Stephen H Petersdorf; Janet F Eary; Joseph G Rajendran; Sharon A Bush; Lawrence D Durack; Jane Golden; Paul J Martin; Dana C Matthews; Frederick R Appelbaum; Irwin D Bernstein; Oliver W Press
Journal:  Blood       Date:  2003-05-15       Impact factor: 22.113

8.  Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas.

Authors:  J M Vose; R L Wahl; M Saleh; A Z Rohatiner; S J Knox; J A Radford; A D Zelenetz; G F Tidmarsh; R J Stagg; M S Kaminski
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

9.  Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma.

Authors:  G L DeNardo; S J DeNardo; D S Goldstein; L A Kroger; K R Lamborn; N B Levy; J P McGahan; Q Salako; S Shen; J P Lewis
Journal:  J Clin Oncol       Date:  1998-10       Impact factor: 44.544

10.  Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Authors:  Jane N Winter; David J Inwards; Stewart Spies; Gregory Wiseman; David Patton; William Erwin; Alfred W Rademaker; Bing Bing Weitner; Stephanie F Williams; Martin S Tallman; Ivana Micallef; Jayesh Mehta; Seema Singhal; Andrew M Evens; Michael Zimmer; Arturo Molina; Christine A White; Leo I Gordon
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544
View more
  5 in total

1.  Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma.

Authors:  Thomas E Witzig; Michael B Tomblyn; Jamal G Misleh; Ebenezer A Kio; Robert M Sharkey; William A Wegener; David M Goldenberg
Journal:  Haematologica       Date:  2014-08-22       Impact factor: 9.941

2.  A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy.

Authors:  Robert M Sharkey; Oliver W Press; David M Goldenberg
Journal:  Blood       Date:  2009-01-30       Impact factor: 22.113

3.  Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants.

Authors:  D Scott Wilbur; Steven I Park; Ming-Kuan Chyan; Feng Wan; Donald K Hamlin; Jaideep Shenoi; Yukang Lin; Shani M Wilbur; Franz Buchegger; Anastasia Pantelias; John M Pagel; Oliver W Press
Journal:  Bioconjug Chem       Date:  2010-07-21       Impact factor: 4.774

4.  Improving the treatment of non-Hodgkin lymphoma with antibody-targeted radionuclides.

Authors:  Robert M Sharkey; Habibe Karacay; David M Goldenberg
Journal:  Cancer       Date:  2010-02-15       Impact factor: 6.860

5.  Review of Y-ibritumomab tiuxetan as first-line consolidation radio-immunotherapy for B-cell follicular non-Hodgkin's lymphoma.

Authors:  Christos Emmanouilides
Journal:  Cancer Manag Res       Date:  2009-10-21       Impact factor: 3.989
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.